CD4 and neoplasm: Similarly, adagrasib decreased intertumoral immunosuppressive myeloid-derived suppressor cells and M2-polarised macrophages and increased immune-promoting M1-polarised macrophages, dendritic cells, CD4+ cells, and NKT cells in KRAS G12C tumours [77].